argenx reports ALKIVIA success. Goldman sets EUR 959 target for Argenx stock

Published on 10/20/2026 at 10:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The Week 52 score beat placebo by 15.4 points on October 19, 2026. Argenx stock costs EUR 743.40 on October 20, 2026 before October 22 results.

Clinical data and reporting dates

ALKIVIA produced a 15.4-point treatment advantage on October 19, 2026.
Second-quarter revenue reached USD 1.54 billion in 2026.
Argenx stock trades at EUR 743.40 at 10:03 a.m. CEST at Lang & Schwarz on October 20, 2026.
Third-quarter results are scheduled for October 22, 2026.

Vogelperspektive-Flatlay: Behandschuhte Hände führen Multikanal-Pipette über 96-Well-Mikrotiterplatte mit blauer Flüssigkeit, weißer Labortisch, symmetrische Komposition — Argenx NL0010832176 Mehrkanal-Pipette befüllt von oben eine blaue 96-Well-Platte im Immunologie-Labor sorgfältig, Illustration mit AI erstellt.

argenx (ISIN NL0010832176) reported a 15.4-point Week 52 improvement advantage for its ALKIVIA study on October 19, 2026. BioSpace reported that Goldman Sachs set a EUR 959.00 target while retaining a Buy rating for argenx on October 16, 2026.

ALKIVIA delivers a measurable endpoint

The Phase 3 trial reached its primary endpoint in autoimmune myositis. At Week 52, the combined immune-mediated necrotizing myopathy and dermatomyositis population recorded a mean Total Improvement Score of 47.95 with efgartigimod versus 32.56 with placebo, according to the company release carried by BioSpace. Improvements appeared by Week 4 and continued through 52 weeks, including during steroid tapering.

Three milestones shape the pipeline

On October 8, 2026, argenx discontinued the Phase 3 UNITY study in Sjogren's disease after an interim futility review, as GlobeNewswire reported. On October 15, 2026, the company scheduled its third-quarter financial results and business update for October 22, 2026. The October 19, 2026 ALKIVIA announcement then supplied the 15.4-point clinical comparison.

What comes next for investors?

The next quantified business test is the third quarter of 2026. In the second quarter, revenue reached USD 1.54 billion and net income was USD 472.0 million, while diluted earnings per share came to USD 7.32. The company has scheduled the results call for October 22, 2026 at 2:30 p.m. CET, according to GlobeNewswire. The ALKIVIA presentation follows on November 11, 2026 during ACR Convergence.

Stock price stays the market marker

For investors, the combination of a positive late-stage data point and the upcoming results date puts clinical execution and commercial growth in the same frame. The stock was trading at EUR 743.40 at Lang & Schwarz on October 20, 2026 at 10:03 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of argenx stock.